GMAB (genmab.com) Enterprise Value-to-Revenue Coefficient

Official company branding of Genmab AS (GMAB)

Genmab A/S net profit relies on royalties from global pharma behemoths, which minimizes dependence on individual studies. The EV/Sales multiple clearly captures the daily market valuation of the business relative to revenue, with the value stabilizing at 8093.20. Unique antibody platforms provide indirect pricing power, while the company's impeccable scientific standing ensures the trust of global oncologists.

genmab.com (GMAB): EV/Sales Multiple from 11/23/2025 to 11/19/2026

Financial and market metric breakdowns for Genmab (GMAB)

- price and consensus price forecast:
- business market valuation indicators:
Fundamental company valuation:Genmab A/S GMAB
Product sample of genmab.com

The development of Genmab A/S's own commercial network as part of its M&A transformation directly impacts capitalization and operating cash flows. The EV/Sales ratio is calculated as the sum of market capitalization and net debt divided by revenue, allowing for a business valuation independent of its financing structure. This chart reflects the efficiency of asset integration and the market's revaluation of the company's ability to independently monetize its drugs.